作者
Christoph Kraus, Ulrich Rabl, Thomas Vanicek, Laura Carlberg, Ana Popovic, Marie Spies, Lucie Bartova, Gregor Gryglewski, Konstantinos Papageorgiou, Rupert Lanzenberger, Matthäus Willeit, Dietmar Winkler, Janusz K Rybakowski, Siegfried Kasper
发表日期
2017/1/2
来源
International journal of psychiatry in clinical practice
卷号
21
期号
1
页码范围
2-12
出版商
Taylor & Francis
简介
Objective: Clinical trials demonstrated that ketamine exhibits rapid antidepressant efficacy when administered in subanaesthetic dosages. We reviewed currently available literature investigating efficacy, response rates and safety profile.
Methods: Twelve studies investigating unipolar, seven on bipolar depression were included after search in medline, scopus and web of science.
Results: Randomized, placebo-controlled or open-label trials reported antidepressant response rates after 24 h on primary outcome measures at 61%. The average reduction of Hamilton Depression Rating Scale (HAM-D) was 10.9 points, Beck Depression Inventory (BDI) 15.7 points and Montgomery-Asberg Depression Rating Scale (MADRS) 20.8 points. Ketamine was always superior to placebo. Most common side effects were dizziness, blurred vision, restlessness, nausea/vomiting and headache, which were all reversible. Relapse …
学术搜索中的文章
C Kraus, U Rabl, T Vanicek, L Carlberg, A Popovic… - International journal of psychiatry in clinical practice, 2017
